Angiolab (XKON:A251280) - Stock Price, News & Analysis

A251280 Stock Overview

A biotechnology company, develops medicine with angiogenesis inhibitors for treating angiogenesis-related diseases. More details

A251280 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Shareholders have been diluted in the past year

Does not have a meaningful market cap (₩25B)

Volatile share price over the past 3 months compared to the KR market

Angiolab, Inc. Competitors

NeoImmuneTech

KOSDAQ:A950220

₩23.9b

GeneBioTech Ltd

KOSDAQ:A086060

₩29.5b

OLIPASS

KOSDAQ:A244460

₩20.6b

Clinomics

KOSDAQ:A352770

₩18.3b

Price History & Performance

Summary of all time highs, changes and price drops for Angiolab
Historical stock prices
Current Share Price	₩8,400.00
52 Week High	₩9,200.00
52 Week Low	₩3,000.00
Beta	0
11 Month Change	20.34%
3 Month Change	9.23%
1 Year Change	4.35%
33 Year Change	-19.62%
5 Year Change	-45.98%
Change since IPO	79.30%

Recent updates

Shareholder Returns

	A251280	KR Biotechs	KR Market
7D	0%	-5.8%	-2.8%
1Y	4.3%	28.2%	-3.4%

Return vs Industry: A251280 underperformed the KR Biotechs industry which returned 28.2% over the past year.

Return vs Market: A251280 exceeded the KR Market which returned -3.4% over the past year.

Price Volatility

Is A251280's price volatile compared to industry and market?
A251280 volatility
A251280 Average Weekly Movement	10.5%
Biotechs Industry Average Movement	8.3%
Market Average Movement	5.7%
10% most volatile stocks in KR Market	11.5%
10% least volatile stocks in KR Market	2.7%

Stable Share Price: A251280's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A251280's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

Founded	Employees	CEO	Website
1999	n/a	Min-Young Kim	www.angiolab.co.kr

Angiolab, Inc., a biotechnology company, develops medicine with angiogenesis inhibitors for treating angiogenesis-related diseases. Its Phase I products consist of AL101-PSO for psoriasis. The company’s Phase II a clinical trial products include AL101- NASH for the treatment of non-alcoholic steatohepatitis; AL101-OME, for otitis media with effusion; and AL102-PDT for periodontitis.

Angiolab, Inc. Fundamentals Summary

How do Angiolab's earnings and revenue compare to its market cap?
A251280 fundamental statistics
Market cap	₩25.11b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A251280 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A251280 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A251280 perform over the long term?

See historical performance and comparison

Angiolab XKON:A251280 Stock Report